Charles Hart, PhD
Director, Catalyst Program
From 2004 to 2017 Charles was at Threshold Pharmaceuticals and responsible for both in vitro and in vivo preclinical translational studies. He was also project leader for the global clinical development program for the hypoxia-targeted anticancer drug evofosfamide (TH-302), a partnership with Merck KGaA. Prior to joining Threshold, Charles was at Galileo Pharmaceuticals (2001 to 2004), Signature Bioscience (2000 to 2001), and Affymax (1990 to 2000). Charles received his PhD in molecular biology and genetics from Yale University in 1987, and completed a postdoctoral fellowship at the University of Strasbourg, France in 1990.
Nate Prorok, MHA
Director, LaunchPad
Senior Program Manager, Catalyst Program
Nate brings a diverse and wide ranging skill set and experience to the Catalyst Program team. After undergraduate studies in Physical Therapy and Athletic Training at Loyola Marymount University, Nathaniel worked with the Jesuit Volunteer Corps - International in Tacna, Perú, with local communities to develop sustainable solutions to the problems they faced in health and education. Afterwards, Nathaniel earned a graduate degree in Healthcare Administration from Marquette University and worked with Children’s Hospital Wisconsin to develop a medical home for youth in foster care. Prior to joining the Catalyst Program, Nathaniel completed a fellowship at the University of Utah Health where he worked on various population health, wellness, and social determinants of health projects.